{"id":82518,"date":"2026-07-07T12:05:14","date_gmt":"2026-07-07T12:05:14","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/"},"modified":"2026-07-07T12:05:14","modified_gmt":"2026-07-07T12:05:14","slug":"spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/","title":{"rendered":"Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1"},"content":{"rendered":"<div>\n<p align=\"center\"><em>\u00a0Completion of enrollment anticipated within 12 months<\/em><\/p>\n<p align=\"center\"><em>GALILEO-3 is intended to support the registration of FLT201 in the adult GD1 population<\/em><\/p>\n<p>LONDON, July  07, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IeP5qbV-X0zxW8YGB-tuYi4hvP7uCsSfRxibkmFkCZdryvS3FLrrG1p4Kg6x76y0nNdRh_TFpXLdjxpi5vvYkzD9djoorfeAoDA1egX6xhw=\" rel=\"nofollow\" target=\"_blank\" title=\"Spur Therapeutics\">Spur Therapeutics<\/a> today announced that the first patient has been dosed in GALILEO-3, its Phase 3 pivotal clinical trial evaluating avigbagene parvec (FLT201), an investigational gene therapy for Gaucher disease type 1 (GD1). The trial will assess the safety and efficacy of FLT201 in adults currently on stable standard-of-care therapies. Spur has aligned with the U.S. Food and Drug Administration (FDA) on a single-arm trial design intended to support regulatory approval.<\/p>\n<p>\u201cDosing the first patient in our Phase 3 trial is an important step forward in our efforts to redefine what is possible for individuals living with Gaucher disease,\u201d said Michael Parini, Chief Executive Officer. \u201cBuilding on the favorable safety and efficacy, including maintenance or improvement in hemoglobin, platelet count, bone disease and organ volume seen in our GALILEO-1 and -2 trials, we are now focused on accelerating this potential best-in-class, one-time treatment toward registration, and the eager response from the community to participate in this trial reflects the real potential for FLT201 to address persistent unmet needs.\u201d<\/p>\n<p>GALILEO-3 is an open-label, non-randomized, global, multicenter, Phase 3 study that will enroll approximately 45 adults with GD1 who have been stable on enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least two years. Participants will receive a single intravenous infusion of FLT201 (4.5 x 10<sup>11<\/sup> vg\/kg) alongside a prophylactic immunosuppressive regimen. The primary endpoint is the proportion of participants maintaining stable hemoglobin concentration at Week 52. Secondary endpoints include safety and tolerability, along with stability of platelet counts, spleen and liver volumes, biomarker changes, bone marrow burden and mineral density changes, and patient-reported quality-of-life outcomes. Spur expects to complete enrollment in the study within 12 months. The study was designed based on learnings from Spur\u2019s GALILEO-1 and GALILEO-2 trials, which demonstrated continuous GCase85 expression, rapid reductions in toxic biomarkers, and no dose-limiting toxicities. More information on the trial design and sites can be found at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RkT5SjvyFDLrS20WecgfHCtNPTIX3V4vEHZLuc6b2OlhhXULgVABG5CsDNBl4G7H0j7f-lr8-42R-3thNn6DWigDL9FodIBMCZXzeTSB0868-1-Qtsjjsmnffq0IjrfI7HjADno53nE1t3xrEc3HiNyBRQDLyJHEgRz9OxQXEqhFyaYZIbxwXncKcU4AiTE_TRpabQnShKL6bfBJ8rPWMw==\" rel=\"nofollow\" target=\"_blank\" title=\"www.clinicaltrials.gov\/study\/NCT07223944\">www.clinicaltrials.gov\/study\/NCT07223944<\/a>.<\/p>\n<p>\u201cThe Gaucher community is eager for further innovation that can move the standard of living care beyond chronic ERT or SRT, which not only require lifelong infusions, but also leave patients with some features of Gaucher disease that are not fully addressed by currently available treatments,\u201d said Dr. Priya Kishnani, Professor of Pediatrics at Duke University and an investigator in GALILEO-3. \u201cThe GALILEO-3 trial will help further evaluate the safety and efficacy of FLT201 and its potential to improve outcomes for the patients we treat.\u201d\u00a0\u00a0<\/p>\n<p>Gaucher disease is a rare genetic disorder caused by mutations in the <em>GBA1<\/em> gene, leading to toxic cellular accumulation and resulting in severe symptoms such as organ enlargement, bone disease, anemia, and debilitating fatigue. While ERT and SRT are the current standards of care, significant unmet medical needs remain. FLT201 is designed to overcome the limitations of these chronic treatments. Utilizing Spur\u2019s proprietary, liver-tropic capsid and an engineered beta-glucocerebrosidase (GCase85), FLT201 delivers continuous, sustained enzyme exposure beyond what is achievable with ERT. This extended stability allows for a low vector genome dose, which is key to a favorable safety profile. FLT201 has both Orphan Drug and RMAT (regenerative medicine advanced therapy) designations from the FDA.<\/p>\n<p><strong>About Spur Therapeutics<\/strong>\u00a0<br \/>Spur Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for debilitating chronic conditions. By optimizing every component of its product candidates, Spur aims to unlock the true potential of gene therapy to realize outsized clinical results. Spur is advancing a breakthrough gene therapy candidate for Gaucher disease and has a preclinical gene therapy candidate for Parkinson\u2019s disease. Expanding our impact, and advancing the practice of genetic medicine.\u00a0<\/p>\n<p>Toward life-changing therapies, and brighter futures. Toward More&#x2122;\u00a0<\/p>\n<p>For more information, visit\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s2nGqpk7ZNsDKL0SVmQzaYsNdbjymqw0IQG7DQ3-F7Zs_tHjTVPNnKnpyYDY7OZ38_zrdPzC3aUarIGdOU2dNUlHt-rlNMf89GRIFBf9MrVebUfp56PeZ78PvG9W73rNWSGSBDSp8X7ZCnyEz7shbl_kTN_mimcFgq3xbA_-EqP_I64HCCjMPYKlOmLcWqS-cWqUj3c9xN_e4CmFfyy2hLA2nighFP8pd0S6G9npSDeieJN8zZms8JvZh9yH9WwAXTJ77poBhS2xDZcKbCMinTuLk9IU00xveryF005bIY-xR-MPKnEEuBaJynoogEJIqyBAf6hWiI1e3pYu8NA0gra8jlEH_SYMn379SVBUSPGnjeMNigqebACDP57pOHhRRXoSu7qa8joqNu2SnsMvOe5hDfmaUcT_3PnQAmRrG7hPEEmHBI9I3ehvjtKePB1c8Rbyh36FksH3LKxd0cC5Q2PkiLUwRFn9-0Oi-jduJ41i4h0xFuOKLnoru-n4J5bb\" rel=\"nofollow\" target=\"_blank\" title=\"www.spurtherapeutics.com\">www.spurtherapeutics.com<\/a>\u202for connect with Spur on\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=b_4cZua2E3WvVa8UuJHDYNHGjaNmMAbaC3OW9hn5DWPKiLR9zjiFDaQwz52kqLDry-gU9V_SAeUHHKgSN3b8SK6dFgOjhRdxh4VwUKogmzPyyFmNm6Tm7xNudLXMunx1rGSyYjlR2AWm8UdUCQYOyFkq7BeZkvkdoN9cHxxPAgDr_f8EXlyljvhSTbDJcYNSzyPqhDf_HxUDI3attmNKgjUTgW61GnQqla_ppp3ZR5h88TbCeCra-E_kN0PhI2zky42KiyTyC3L1Ia40ptn8mMQgLGDFoPrr4gGKDs3-ZcKWrDL4dRmVFcV186a-Nc1kYHozTRLhgJYepBsbhn6mNeGrc4DMpEeFU88v7Oewsj6vBiV0SqG_V6FSiXoxtDFhm7_JmZaN7YRzDD2Vr-9VyV5_C6bOhN4e4DfGv77QjQkY8juXB7YdT-Uugy_S4f9JhkNmKa2NwutdSf821LNnr5T-5PIBjND3HF6UxgXKnEc=\" rel=\"nofollow\" target=\"_blank\" title=\"LinkedIn\">LinkedIn<\/a>.\u00a0<\/p>\n<p><strong>Contact<\/strong>\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FssGh4_G5EHgZ3NzaRb7gr6HBMaUPIpIqY0TYBSVCQg4PCfdwgSKmICXzyAbNisf3Ktdiyl4EtW-msKpkX80aaHGPFWGz2ejOrQo0dQ7qpWo8LDYWMgadNPXujGEVBbm\" rel=\"nofollow\" target=\"_blank\" title=\"media@spurtherapeutics.com\">media@spurtherapeutics.com<\/a>\u00a0<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDM1MjA1MWEtNTEwNC00YWIxLTgwY2UtYmY5NDk4YzlkMjg1LTEyNzQ1MDEtMjAyNi0wNy0wNy1lbg==\/tiny\/Spur-Therapeutics.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0Completion of enrollment anticipated within 12 months GALILEO-3 is intended to support the registration of FLT201 in the adult GD1 population LONDON, July 07, 2026 (GLOBE NEWSWIRE) &#8212; Spur Therapeutics today announced that the first patient has been dosed in GALILEO-3, its Phase 3 pivotal clinical trial evaluating avigbagene parvec (FLT201), an investigational gene therapy [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-82518","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-people"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1 - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1\" \/>\n<meta property=\"og:description\" content=\"\u00a0Completion of enrollment anticipated within 12 months GALILEO-3 is intended to support the registration of FLT201 in the adult GD1 population LONDON\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-07T12:05:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/05\/SaigonBiz-Feature-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1074\" \/>\n\t<meta property=\"og:image:height\" content=\"716\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1\",\"datePublished\":\"2026-07-07T12:05:14+00:00\",\"dateModified\":\"2026-07-07T12:05:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/\"},\"wordCount\":663,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"People\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/\",\"name\":\"Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1 - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-07-07T12:05:14+00:00\",\"dateModified\":\"2026-07-07T12:05:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1 - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/","og_locale":"en_US","og_type":"article","og_title":"Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1","og_description":"\u00a0Completion of enrollment anticipated within 12 months GALILEO-3 is intended to support the registration of FLT201 in the adult GD1 population LONDON","og_url":"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-07-07T12:05:14+00:00","og_image":[{"width":1074,"height":716,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/05\/SaigonBiz-Feature-Image.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1","datePublished":"2026-07-07T12:05:14+00:00","dateModified":"2026-07-07T12:05:14+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/"},"wordCount":663,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["People"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/","url":"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/","name":"Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1 - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-07-07T12:05:14+00:00","dateModified":"2026-07-07T12:05:14+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-trial-of-flt201-for-the-treatment-of-gaucher-disease-type-1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/82518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=82518"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/82518\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=82518"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=82518"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=82518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}